Skip to main content
Publications
Wolf J, Garon EB, Groen HJM, Tan DSW, Gilloteau I, Le Mouhaer S, Hampe M, Cai C, Chassot-Agostinho C, Reynolds M, Sherif B, Heist RS. Patient-reported outcomes in capmatinib-treated patients with METex14-mutated advanced NSCLC: results from the GEOMETRY mono-1 study. Eur J Cancer. 2023 Apr;183:98-108. doi: 10.1016/j.ejca.2022.10.030
Ribera A, Gimenez E, Oristrell G, Osorio D, Marsal JR, Garcia-Perez L, Ballesteros M, Rodenas E, Belahnech Y, Escalona R, Rivas N, Roca-Luque I, Ferreira-Gonzalez I, Espallargues M. Cost-effectiveness of implantable cardioverter-defibrillators for primary prevention of sudden cardiac death. Rev Esp Cardiol (Engl Ed). 2022 Jan;75(1):12-21. doi: 10.1016/j.rec.2021.05.004
Smith MR, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Kuss I, Le Berre MA, Mohamed AF, Odom D, Bartsch J, Snapir A, Sarapohja T, Fizazi K. Darolutamide and health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the phase III ARAMIS trial. Eur J Cancer. 2021 Jul 14;154:138-46.
Dubner SJ, Teutsch C, Huisman MV, Diener H-C, Halperin J, Rothman KJ, Ma C-S, Chuquiure-Valenzuela E, Bergler-Klein J, Zint K, Franca LR, Lu S, Paquette M, Lip GYH. Characteristics and 2-year outcomes of dabigatran treatment in patients with heart failure and atrial fibrillation: GLORIA-AF. ESC Heart Fail. 2020 Oct;7(5):2679-89. doi: 10.1002/ehf2.12857
Galian-Gay L, Gordon B, Marsal JR, Rafecas A, Pijuan Domenech A, Castro MA, Subirana Domenech MT, Sureda C, Miranda B, Marti G, Garcia-Dorado D, Dos Subira L. Determinants of long-term outcome of repaired pulmonary valve stenosis. Rev Esp Cardiol (Engl Ed). 2020 Feb;73(2):131-8.
Caballero-Banos M, Benitez-Ribas D, Tabera J, Varea S, Vilana R, Bianchi L, Ayuso JR, Pages M, Carrera G, Cuatrecasas M, Martin-Richard M, Cid J, Lozano M, Castells A, Garcia-Albeniz X, Maurel J, Vilella R. Phase II randomised trial of autologous tumour lysate dendritic cell plus best supportive care compared with best supportive care in pre-treated advanced colorectal cancer patients. Eur J Cancer. 2016 Sep;64:167-74. doi: 10.1016/j.ejca.2016.06.008
Alonso-Espinaco V, Cuatrecasas M, Alonso V, Escudero P, Marmol M, Horndler C, Ortego J, Gallego R, Codony-Servat J, Garcia-Albeniz X, Jares P, Castells A, Lozano JJ, Rosell R, Maurel J. RAC1b overexpression correlates with poor prognosis in KRAS/BRAF WT metastatic colorectal cancer patients treated with first-line FOLFOX/XELOX chemotherapy. Eur J Cancer. 2014 Jul;50(11):1973-81. doi: 10.1016/j.ejca.2014.04.019